Lipopolysaccharide stimulates dynamic changes in B cell metabolism to promote proliferation

This study demonstrates that TLR-mediated B cell activation requires metabolic reprogramming characterized by upregulated amino acid uptake via SLC7A5 and increased cholesterol biosynthesis to drive proliferation.

The Gist

Imagine your body's immune system as a highly trained security force. Among its ranks are B cells, the "special forces" responsible for producing antibodies (the weapons) to fight off invaders like bacteria.

When these B cells are resting, they are like soldiers in a quiet barracks: they are small, calm, and don't need much food or energy. They are in a state of "quiescence." But when a threat appears—specifically a bacterial invader carrying a molecule called LPS (Lipopolysaccharide)—these soldiers are called to action. They must instantly transform from quiet guards into a massive, rapidly multiplying army.

This paper is a detailed investigation into how these B cells pull off this massive transformation. The researchers discovered that to grow and multiply, B cells need to completely overhaul their internal "supply chain" and "factory." Here is the breakdown of their findings using simple analogies:

1. The "Factory" Expansion (Protein Synthesis)

To build an army, you need to build millions of new soldiers. This means the B cell needs to manufacture a huge amount of new proteins.

• The Problem: A resting cell doesn't have enough raw materials (amino acids) to build a factory.
• The Solution: The study found that activated B cells immediately install massive new "loading docks" on their surface. Specifically, they boost a transporter called SLC7A5.
• The Analogy: Think of SLC7A5 as a super-fast conveyor belt that sucks in essential building blocks (amino acids) from the outside world. The researchers found that if you block this conveyor belt, the B cell cannot build its army and the soldiers die. It's like trying to build a skyscraper but having the construction site cut off from the delivery trucks; the project grinds to a halt.

2. The "Road Paving" Requirement (Cholesterol)

Cells need to grow in size and divide. To do this, they need to build new cell membranes (the outer skin of the cell). A key ingredient for this skin is cholesterol.

• The Discovery: The researchers found that activated B cells don't just wait for cholesterol to arrive; they start building their own. They turn on the internal "cholesterol factory" (enzymes like HMG-CoA reductase) and also open the gates to grab cholesterol from the blood (via LDL receptors).
• The Analogy: Imagine the cell is a city that needs to expand its borders. Cholesterol is the asphalt needed to pave the new roads. The study showed that if you use a "statin" drug (like Fluvastatin, which blocks the cholesterol factory) to stop the B cell from making asphalt, the city cannot expand. The army cannot grow, and the soldiers stop multiplying.

3. The "Secret Ingredient" (Prenylation)

This is the most surprising part of the story. The researchers thought the problem with statins was just a lack of cholesterol (the asphalt). But they discovered something deeper.

• The Twist: The cholesterol factory also produces a byproduct used for prenylation. This is a chemical process that acts like a "glue" or a "GPS tag" for certain proteins inside the cell. These proteins need to be "glued" to the cell membrane to work properly.
• The Analogy: Think of the cell's internal machinery as a fleet of delivery trucks. Prenylation is the GPS system that tells the trucks where to go. If you block the cholesterol factory, you also break the GPS system. The trucks (proteins) get lost, and the delivery system fails.
• The Proof: The researchers tried to fix the problem by adding back just the "GPS glue" (a molecule called GGPP) without fixing the cholesterol. Surprisingly, this saved the B cells! This proved that the B cells need the "glue" just as much as, if not more than, the cholesterol itself to survive and multiply.

4. It's Not Just One Signal

The study also checked if this was a special trick only for LPS. They tested other triggers, like different bacterial signals or direct contact with helper T-cells.

• The Result: Every time the B cell was told to fight, it used this same strategy: Open the amino acid gates, build cholesterol, and glue the internal proteins. It's a universal "battle mode" switch for B cells.

Why Does This Matter?

This research is a game-changer for understanding how our immune system works.

1. Vaccines and Infections: It explains exactly how our body ramps up its defenses when we get sick.
2. Autoimmune Diseases: Sometimes the immune system attacks the body (like in Lupus or Rheumatoid Arthritis). If we can understand the "supply chain" these bad B cells use, we might be able to shut them down.
3. Cancer: Some blood cancers are essentially B cells that are stuck in "battle mode" and won't stop multiplying. Targeting their cholesterol or amino acid supply could be a new way to treat these cancers.

In a nutshell:
When a B cell gets the call to fight, it doesn't just wake up; it undergoes a massive construction project. It builds new loading docks to grab food, opens a factory to make road-paving material (cholesterol), and installs a GPS system (prenylation) to keep its internal machinery running. If you block any of these three steps, the army collapses, and the infection wins.

Technical Summary

1. Problem Statement

Naïve B cells exist in a quiescent state with low metabolic demand. Upon activation by antigens or Toll-like receptor (TLR) ligands (such as Lipopolysaccharide/LPS), they must rapidly exit quiescence, proliferate, and differentiate into antibody-secreting plasma cells or memory B cells. This transition requires a massive increase in the synthesis of proteins, lipids, and nucleic acids.

While glucose metabolism (glycolysis and the pentose phosphate pathway) in activated B cells is well-documented, the broader proteomic landscape of metabolic reprogramming—specifically regarding amino acid uptake and lipid metabolism (cholesterol)—remains poorly understood. Previous studies lacked a comprehensive proteomic analysis of how B cells rewire their metabolism to support the energetic and biosynthetic demands of TLR-mediated activation.

2. Methodology

The study employed a multi-faceted approach combining quantitative proteomics, genetic models, pharmacological inhibition, and metabolic tracing:

• Experimental Model: Murine B cells (from C57BL/6 mice) were isolated from lymph nodes and spleens. They were stimulated ex vivo with LPS (TLR4 agonist) and Interleukin-4 (IL-4) to induce T-cell-independent type I activation.
• Quantitative Proteomics:
  • Technique: Data Independent Acquisition (DIA) mass spectrometry was used to compare naïve B cells vs. LPS+IL-4 stimulated B cells (24 hours post-stimulation).
  • Analysis: The "Proteomic Ruler" method was applied to estimate protein copy numbers and concentrations. Gene Ontology (GO) and KEGG pathway enrichment analyses were performed.
• Genetic Models:
  • Conditional Knockout: Slc7a5 (encoding the amino acid transporter LAT1) was deleted in hematopoietic cells using Vav-iCre mice (Slc7a5^fl/fl/Vav-iCre⁺).
  • MyD88 Knockout: Used to confirm TLR4 signaling dependency.
• Pharmacological Inhibition:
  • Cholesterol Pathway: Fluvastatin (HMG-CoA reductase inhibitor) and NB-598 (Squalene monooxygenase inhibitor).
  • Prenylation Pathway: FGTI-2734 (dual FTase/GGTase inhibitor), FTI-277 (FTase inhibitor), and GGTI-298 (GGTase inhibitor).
  • Signaling Pathways: PD184352 (MEK1/2 inhibitor), VX745 (p38 inhibitor), and Rapamycin (mTOR inhibitor).
  • Rescue Experiments: Supplementation with Mevalonate (downstream of HMG-CoA reductase) and Geranylgeranyl pyrophosphate (GGPP).
• Metabolic Assays:
  • Proliferation: Cell Trace Violet (CTV) dilution.
  • Protein Synthesis: O-propargyl-puromycin (OPP) incorporation.
  • Amino Acid Uptake: Kynurenine uptake assay (substrate for SLC7A5).
  • Cholesterol Levels: Filipin staining (fluorescent cholesterol binding).
  • Lipid Uptake: Use of silica-depleted serum (cholesterol-free media) to distinguish between de novo synthesis and LDL uptake.

3. Key Contributions

The paper provides the first comprehensive proteomic map of metabolic rewiring in LPS-activated B cells, revealing two critical, previously underappreciated dependencies:

1. Essential Role of SLC7A5: Identification of the amino acid transporter SLC7A5 (LAT1) as a non-redundant driver of B cell proliferation.
2. Dual Requirement for Cholesterol and Prenylation: Demonstration that B cell proliferation relies not only on cholesterol biosynthesis for membrane expansion but also on protein prenylation (specifically geranylgeranylation) for signaling and vesicle trafficking.

4. Key Results

A. Proteomic Reprogramming

• Global Changes: LPS+IL-4 stimulation increased total cellular protein mass by ~2-fold. While most proteins scaled with cell size, specific subsets were selectively upregulated.
• Pathways: Upregulated proteins were enriched in cell cycle, ribosome biogenesis, protein translation, and steroid biosynthesis. Surprisingly, glycolytic enzymes did not show significant concentration changes, though mitochondrial volume increased.
• Cell Cycle: Rapid upregulation of Cyclin D, CDK4/6, and phosphorylation of RB1, alongside downregulation of p27^Kip1, confirming G1/S transition.

B. Amino Acid Metabolism (SLC7A5)

• Upregulation: The System L amino acid transporter subunit SLC7A5 (and its partner SLC3A2/CD98) was markedly upregulated at both mRNA and protein levels.
• Function: SLC7A5 is responsible for the uptake of large neutral amino acids (e.g., leucine, tryptophan) and kynurenine.
• Necessity: Conditional deletion of Slc7a5 in B cells resulted in a complete failure to proliferate and survive upon LPS stimulation, despite normal naïve B cell development. Kynurenine uptake was abolished in these knockout cells.

C. Cholesterol Metabolism and Prenylation

• Upregulation: Enzymes of the mevalonate pathway (HMGCR, SQLE) and the LDL receptor (LDLR) were upregulated. Intracellular cholesterol levels (measured by filipin) increased significantly.
• Biosynthesis vs. Uptake: B cells increased cholesterol via both de novo synthesis and LDL uptake. In cholesterol-free media, cells relied entirely on synthesis; in normal media, they utilized both.
• Inhibition Effects:
  • Inhibiting HMG-CoA reductase (Fluvastatin) or Squalene monooxygenase (NB-598) blocked proliferation and reduced cell size.
  • Prenylation is Critical: The mevalonate pathway produces intermediates for both cholesterol and protein prenylation. Inhibiting prenylation (FGTI-2734) mimicked the effects of statins. Specifically, Geranylgeranyl Transferase (GGTase) inhibition (GGTI-298) was more potent than Farnesyl Transferase (FTase) inhibition, suggesting geranylgeranylation is the critical step.
• Rescue Mechanisms:
  • Mevalonate: Partially rescued Fluvastatin effects in normal media but failed in cholesterol-free media.
  • GGPP: Geranylgeranyl pyrophosphate (GGPP) fully rescued proliferation and survival in normal media, even better than mevalonate.
  • Mechanism: GGPP rescued cholesterol levels in normal media (likely by restoring LDLR endocytosis via prenylated Rab GTPases) but failed in cholesterol-free media. This indicates a dual requirement: cholesterol is needed for membrane expansion, and prenylation is needed for the machinery (LDLR trafficking) to acquire cholesterol.

D. Signaling Pathways

• MAPK and mTOR: Inhibition of p38, MEK1/2, and mTOR reduced proliferation and cholesterol levels.
• mTOR: While mTOR inhibition reduced protein synthesis and amino acid uptake, it did not completely block them, suggesting parallel regulation.
• Generality: These metabolic requirements (cholesterol/prenylation) were observed across multiple activation stimuli (TLR7, TLR9, CD40, BCR), indicating a universal feature of B cell activation.

5. Significance

• Therapeutic Potential: The findings suggest that statins (HMG-CoA reductase inhibitors) and prenylation inhibitors could modulate B cell responses. This is relevant for treating autoimmune diseases (where B cell hyperactivity is a driver) or enhancing vaccine responses.
• Metabolic Paradigm: The study shifts the focus from glucose-centric views of B cell activation to a broader understanding involving lipid metabolism and amino acid transport.
• Mechanistic Insight: It elucidates a complex feedback loop where prenylation is required for cholesterol uptake (via LDLR trafficking), creating a dual dependency that makes B cells highly sensitive to mevalonate pathway inhibitors.
• Proteomic Benchmark: Provides a high-resolution proteomic dataset of B cell activation, serving as a resource for future immunometabolism research.

In conclusion, the paper establishes that successful B cell proliferation is strictly dependent on the coordinated upregulation of amino acid transport (via SLC7A5) and the mevalonate pathway, which supplies both cholesterol for membrane biogenesis and prenyl groups for essential signaling and trafficking proteins.